This study is in progress, not accepting new patients
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Summary
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Links
- Mirum Pharmaceuticals homepage Genetics Home Reference - ALGS
- ID
- NCT04729751
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 12 study participants
- Last Updated